Spyre Therapeutics (SYRE) Competitors

$74.07 -1.58 (-2.09%)

As of 02:59 PM Eastern

SYRE vs. ROIV, MRNA, VTRS, GMAB, and ASND

Should you buy Spyre Therapeutics stock or one of its competitors? MarketBeat compares Spyre Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyre Therapeutics include Roivant Sciences (ROIV), Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does Spyre Therapeutics compare to Roivant Sciences?

Spyre Therapeutics (NASDAQ:SYRE) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Spyre Therapeutics had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Spyre Therapeutics and 7 mentions for Roivant Sciences. Spyre Therapeutics' average media sentiment score of 1.03 beat Roivant Sciences' score of 0.66 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has higher earnings, but lower revenue than Roivant Sciences. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,227.43	-$155.20M	-$2.08	N/A
Roivant Sciences	$29.05M	721.39	-$171.98M	-$1.17	N/A

Spyre Therapeutics currently has a consensus price target of $90.25, indicating a potential upside of 21.84%. Roivant Sciences has a consensus price target of $30.55, indicating a potential upside of 4.33%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Spyre Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Spyre Therapeutics has a beta of 3.12, meaning that its share price is 212% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

Summary

Spyre Therapeutics beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Moderna?

Spyre Therapeutics (NASDAQ:SYRE) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Spyre Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Moderna	-143.55%	-26.64%	-19.32%

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Moderna had 15 more articles in the media than Spyre Therapeutics. MarketBeat recorded 25 mentions for Moderna and 10 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.03 beat Moderna's score of 0.67 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	14 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Spyre Therapeutics has a beta of 3.12, meaning that its stock price is 212% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Spyre Therapeutics has higher earnings, but lower revenue than Moderna. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,227.43	-$155.20M	-$2.08	N/A
Moderna	$1.94B	9.99	-$2.82B	-$8.15	N/A

Spyre Therapeutics currently has a consensus price target of $90.25, indicating a potential upside of 21.84%. Moderna has a consensus price target of $35.73, indicating a potential downside of 27.02%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Spyre Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Summary

Spyre Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Viatris?

Spyre Therapeutics (NASDAQ:SYRE) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Spyre Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Viatris	-2.04%	19.04%	7.62%

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 1 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Spyre Therapeutics and 9 mentions for Viatris. Spyre Therapeutics' average media sentiment score of 1.03 beat Viatris' score of 0.68 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a beta of 3.12, meaning that its share price is 212% more volatile than the broader market. Comparatively, Viatris has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Spyre Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,227.43	-$155.20M	-$2.08	N/A
Viatris	$14.30B	1.35	-$3.51B	-$0.26	N/A

Spyre Therapeutics currently has a consensus price target of $90.25, suggesting a potential upside of 21.84%. Viatris has a consensus price target of $15.71, suggesting a potential downside of 4.91%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spyre Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Spyre Therapeutics beats Viatris on 13 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Spyre Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 10 mentions for Spyre Therapeutics and 8 mentions for Genmab A/S. Spyre Therapeutics' average media sentiment score of 1.03 beat Genmab A/S's score of 0.66 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.27	$963M	$1.32	20.22
Spyre Therapeutics	$890K	7,227.43	-$155.20M	-$2.08	N/A

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.12, meaning that its stock price is 212% more volatile than the broader market.

Genmab A/S presently has a consensus price target of $39.07, suggesting a potential upside of 46.39%. Spyre Therapeutics has a consensus price target of $90.25, suggesting a potential upside of 21.84%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Genmab A/S has a net margin of 21.05% compared to Spyre Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Genmab A/S and Spyre Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Spyre Therapeutics had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 10 mentions for Spyre Therapeutics and 9 mentions for Ascendis Pharma A/S. Spyre Therapeutics' average media sentiment score of 1.03 beat Ascendis Pharma A/S's score of 0.47 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.49	-$258M	$8.67	27.86
Spyre Therapeutics	$890K	7,227.43	-$155.20M	-$2.08	N/A

80.4% of Spyre Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.12, meaning that its stock price is 212% more volatile than the broader market.

Ascendis Pharma A/S presently has a consensus price target of $291.78, suggesting a potential upside of 20.81%. Spyre Therapeutics has a consensus price target of $90.25, suggesting a potential upside of 21.84%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Spyre Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has a net margin of 57.87% compared to Spyre Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.

Get Spyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRE vs. The Competition

Export

Metric	Spyre Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.44B	$3.31B	$6.23B	$12.35B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-35.67	18.15	20.41	25.39
Price / Sales	7,227.43	281.36	541.58	73.15
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	12.49	6.74	9.83	6.93
Net Income	-$155.20M	$24.11M	$3.56B	$333.88M
7 Day Performance	-1.29%	3.92%	0.52%	0.03%
1 Month Performance	7.37%	-2.85%	-0.71%	1.93%
1 Year Performance	409.44%	68.91%	36.34%	33.14%

Spyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRE Spyre Therapeutics	2.7185 of 5 stars	$74.07 -2.1%	$90.25 +21.8%	+411.1%	$6.44B	$890K	N/A	73	Positive News Analyst Forecast
ROIV Roivant Sciences	2.2232 of 5 stars	$28.31 -0.2%	$30.55 +7.9%	+176.5%	$20.26B	$29.05M	N/A	860	Upcoming Earnings
MRNA Moderna	1.4656 of 5 stars	$46.68 -1.3%	$35.73 -23.4%	+108.3%	$18.44B	$2.20B	N/A	4,700	Gap Down
VTRS Viatris	2.5343 of 5 stars	$15.53 +2.2%	$14.67 -5.6%	+105.0%	$18.08B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.2689 of 5 stars	$27.53 +1.8%	$39.07 +41.9%	+41.0%	$17.16B	$3.72B	17.76	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRE) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyre Therapeutics (SYRE) Competitors

SYRE vs. ROIV, MRNA, VTRS, GMAB, and ASND

How does Spyre Therapeutics compare to Roivant Sciences?

Summary

How does Spyre Therapeutics compare to Moderna?

Summary

How does Spyre Therapeutics compare to Viatris?

Summary

How does Spyre Therapeutics compare to Genmab A/S?

Summary

How does Spyre Therapeutics compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyre Therapeutics (SYRE) Competitors

SYRE vs. ROIV, MRNA, VTRS, GMAB, and ASND

How does Spyre Therapeutics compare to Roivant Sciences?

Do institutionals and insiders have more ownership in SYRE or ROIV?

Does the media favor SYRE or ROIV?

Which has preferable earnings & valuation, SYRE or ROIV?

Do analysts prefer SYRE or ROIV?

Which has more volatility and risk, SYRE or ROIV?

Is SYRE or ROIV more profitable?

Summary

How does Spyre Therapeutics compare to Moderna?

Is SYRE or MRNA more profitable?

Do insiders & institutionals have more ownership in SYRE or MRNA?

Does the media favor SYRE or MRNA?

Which has more risk and volatility, SYRE or MRNA?

Which has better valuation and earnings, SYRE or MRNA?

Do analysts prefer SYRE or MRNA?

Summary

How does Spyre Therapeutics compare to Viatris?

Is SYRE or VTRS more profitable?

Do insiders & institutionals have more ownership in SYRE or VTRS?

Does the media refer more to SYRE or VTRS?

Which has more risk & volatility, SYRE or VTRS?

Which has preferable valuation & earnings, SYRE or VTRS?

Do analysts prefer SYRE or VTRS?

Summary

How does Spyre Therapeutics compare to Genmab A/S?

Does the media prefer GMAB or SYRE?

Which has higher earnings and valuation, GMAB or SYRE?

Do institutionals & insiders hold more shares of GMAB or SYRE?

Which has more volatility & risk, GMAB or SYRE?

Do analysts recommend GMAB or SYRE?

Is GMAB or SYRE more profitable?

Summary

How does Spyre Therapeutics compare to Ascendis Pharma A/S?

Does the media prefer ASND or SYRE?

Which has higher earnings and valuation, ASND or SYRE?

Do institutionals & insiders hold more shares of ASND or SYRE?

Which has more volatility & risk, ASND or SYRE?

Do analysts recommend ASND or SYRE?

Is ASND or SYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools